Nat Commun:上海药物所领衔团队在生物纳米材料领域取得新突破

2018-07-05 俞淼荣 iNature

2018年7月4日,《自然-通讯》杂志以“Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers”为题,在线报道了中科院上海药物所和国家纳米科学中心合作的最新研究成果。

2018年7月4日,《自然-通讯》杂志以“Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers”为题,在线报道了中科院上海药物所和国家纳米科学中心合作的最新研究成果。

与传统的给药方式相比,将药物分子搭载到纳米药物载体上可以实现药物的高效精确传递和可控释放。近年来,这种新型的给药方式在改善药物口服吸收和肿瘤治疗中已经取得了突破性的研究成果。然而,与简单的体外实验环境相比,纳米药物载体在到达靶组织和靶细胞之前需要克服生物体内的多重生理病理屏障,如:酶屏障、黏液屏障、细胞间质屏障、细胞屏障以及胞内转运屏障等。因此,为实现疗效最大化,设计和制备能够克服多重生理屏障并且具备高效的细胞摄入量的新型递送载体成为纳米药物从实验室转向临床应用的一个重要挑战。

前期,中国科学院上海药物研究所甘勇研究员和国家纳米中心施兴华研究员团队结合分子动力学模拟和超分辨率显微镜技术,发现棒状粒子特有的“旋转-跳跃”运动方式能促进其在网格状黏蛋白液体内的扩散速度,可有效提高递药效率,并提出了一个考虑颗粒黏附效应的障碍-扩散理论模型。相关成果陆续发表于Nano Letters 16, 7176-7182 (2016);固体力学旗舰期刊Journal of the Mechanics and Physics of Solids 112: 431-457 (2018)。同时,双方又发现制约纳米载体口服递药和肿瘤递药的共性生理因素:具有网状结构的生物凝胶(如黏液和肿瘤细胞间质)在药物载体抵达靶细胞前扮演了重要的阻滞作用,且单一调节载体的尺度、表面性质等往往不能够有效地克服递药过程中的多重生理屏障。

启发于肿瘤细胞较正常细胞具有更低的杨氏模量(刚度),加速肿瘤细胞的转移和扩散,研究人员考察不同刚柔性纳米药物载体在克服胞内外多重屏障的能力。采用微流控技术,设计制备了以磷脂膜为壳、聚丙交酯乙交酯共聚物(PLGA)为核的纳米颗粒载体。通过调节载体的力学性能,发现刚度适中的载体在生物凝胶中具有最高的扩散系数,且比不含PLGA内核的脂质体扩散系数提高10倍,进而拥有最优的细胞摄取量和药物递送能力。相关高效递药效果也在生物体内获得了验证。随后,结合高分辨显微镜观测和分子模拟技术,研究者对药物载体的力学性能调节其在生物凝胶屏障中扩散的力学机制进行了解析,即颗粒越软,易于变形,则载体与黏蛋白组织产生更强吸附影响其扩散;而过硬的颗粒不易变形,则容易陷入黏蛋白网络,也难以实现高效扩散。进而发现刚度适中的颗粒具有适宜的变形能力,易于穿越生物凝胶、细胞膜等多重屏障,具有最优的递药能力。这些发现将有助于科学家们利用物理属性(如形状、力学性能等)设计高效的药物载体。

该研究得到国家自然科学基金和中国科学院战略性先导科技专项的资助。来自上海交通大学和国家蛋白质中心的研究人员以多种方式提供了支持和帮助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
    2018-10-26 zxxiang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
    2018-12-11 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
    2019-06-07 liye789132251
  6. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
    2018-07-05 医者仁心5538

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1798563, encodeId=621f1e9856362, content=<a href='/topic/show?id=b5d96943076' target=_blank style='color:#2F92EE;'>#生物纳米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69430, encryptionId=b5d96943076, topicName=生物纳米)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Oct 04 03:05:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972181, encodeId=ad4b19e2181d7, content=<a href='/topic/show?id=1212199e12e' target=_blank style='color:#2F92EE;'>#上海药物所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19971, encryptionId=1212199e12e, topicName=上海药物所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03e7496, createdName=楚钟, createdTime=Sat Feb 16 08:05:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724984, encodeId=74e11e2498420, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Fri Oct 26 00:05:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087379, encodeId=30da208e3792a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 11 18:05:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883157, encodeId=597e188315eb5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 07 07:05:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479485, encodeId=e7a314e948597, content=<a href='/topic/show?id=1e30e739295' target=_blank style='color:#2F92EE;'>#纳米材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77392, encryptionId=1e30e739295, topicName=纳米材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cde87531954, createdName=12498710m13暂无昵称, createdTime=Sat Jul 07 04:05:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329527, encodeId=8d3e32952e67, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Jul 05 14:15:48 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329508, encodeId=bcd13295086a, content=不错的.学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdqKgfW3nMpOkC3jXxiaW2po0PtglY5ZuVjERqKADW4HyMI8bcZXWlKgH7tEP9ULBoBzuQMibia4pr1s9rQPqLvqQJ/0, createdBy=e8c02060444, createdName=中医痴, createdTime=Thu Jul 05 13:23:19 CST 2018, time=2018-07-05, status=1, ipAttribution=)]
    2018-07-05 中医痴

    不错的.学习了.谢谢分享.

    0

相关资讯

Radiology:小小蛋白冠,MR成像细胞示踪大作用!

本研究旨在评估是否在体MRI示踪时,纳米氧化铁周围的蛋白冠形成有易于干细胞标记来进行追踪,并将结果发表在Radiology上。

Nature Biotech:DNA纳米机器人精准靶向癌症

我们目前对抗恶性肿瘤的方法还远远不够,常见的化疗和放射治疗有时很成功,但也会带来巨大的副作用。这主要是因为体内的健康细胞也会被“连累”受到化学物质和辐射的“轰击”。

Nat Commun:研究人员开发的全新纳米药物抗癌效果更显著!

特拉维夫大学的一项新研究指出,已知癌基因(一种促进癌症发生的基因)和一种抑癌基因microRNA的表达之间的负相关性是导致胰腺癌延长生存的原因。该研究可以作为开发这种致命疾病和其他癌症的有效鸡尾酒药物的基础。

Nat Commu:上海硅酸盐所提出“纳米催化医学”肿瘤治疗新策略

癌症是少数现代医学仍然无法攻克的疾病之一,癌细胞以其复杂多样的代谢方式和生态微环境给癌症治疗带来极大的困难。在目前癌症的治疗策略中,化疗仍是最常用的手段之一。但常规的癌症化疗,在高毒性的药物作用于全身造成强烈毒副作用的同时,病灶的药效却随之大幅降低。事实上,强毒副作用与低化疗效果成为了癌症病人的主要死亡原因之一。因此,开发无毒、安全和高效的癌症治疗体系尤为重要。

纳米技术立大功,科学家开发出纳米机器人可以在60秒内杀死癌细胞

纳米技术可以钻入癌细胞,在60秒内杀死它们,科学家们已经开发出来了。

Trends Biotechnol:安全有效使用纳米材料抗癌?肿瘤异质性至关重要!

纳米粒子抗癌疗法日趋火热,而使用该治疗疗法所带来的有效性和安全性问题却有待解决。最新研究表明使用该抗癌疗法必须考虑灌注质量、癌症干细胞等级和可兑换性。其他重要因素还包括表观遗传学改变,增强渗透和保留效应以及网状内皮系统的影响。